1887

Abstract

Summary

The isoquinoline drugs UK2054 and UK2371 were tested for activity against rhino-viruses. UK2054, but not UK2371, decreased the yield of rhinovirus types 2, 4, 9 and 43 from HeLa cells maintained in medium containing the drug. This activity was not demonstrable in a semi-continuous line of human embryo lung fibroblasts, HEL-218. In a double-blind, placebo-controlled trial, human volunteers were experimentally infected with rhinovirus type 9 and given prophylactic and therapeutic UK2054 by mouth. No significant antiviral activity was found in this trial.

We thank Messrs Pfizer Ltd for supplies of drug and placebo tablets, Miss M. D. Turnbull for help with clinical observations, and Mrs Susan Finniss for valuable technical assistance. We also thank Dr D. A. J. Tyrrell and Dr E. J. Stott for much helpful advice.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/00222615-3-2-346
1970-05-01
2020-01-23
Loading full text...

Full text loading...

http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/00222615-3-2-346
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error